Drug Profile
Research programme: cancer diagnostic and therapeutic agents - Kereos
Alternative Names: KER 0001; KER 1001; KER 1002; KER 1003; KI 001; KI-0001; KI-0003; KI-1001; KI-1003 - Kereos; KI-100X; Melittin nanoparticles - Kereos; Mellitin nanoparticles - Kereos; Nanobees - KereosLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Washington University School of Medicine
- Developer Kereos
- Class Diagnostic agents; Pore forming cytotoxic proteins
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Solid tumours (Diagnosis) in USA (IV)
- 22 Feb 2023 Discontinued - Preclinical for Solid tumours in USA (IV)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV, Injection)